Amgen Price Target Raised to $440.00/Share From $384.00 by Canaccord Genuity

What happened

Canaccord Genuity raised its price target for Amgen to $440.00 per share from $384.00 per share. The same ratings update says the firm maintained its Hold rating on Amgen.

Confirmed

Global impact / market context

A price target is an analyst’s estimate of a stock’s value, not a promised trading price. Raising it signals a more favorable valuation view, while keeping the Hold rating indicates Canaccord did not change its overall recommendation; neither action directly changes Amgen’s revenue or costs.

Analyst inference

The supplied report gives no reason for the higher target, financial forecast, or evidence of a change in Amgen’s business. Investors therefore have little basis here to connect the revision to expected sales, research spending, cash available, or the company’s operating outlook.

Analyst inference

What to watch

1. Look for Canaccord’s explanation of the $440.00 target and its assumptions about Amgen’s sales, costs, or cash generation, which could show what supports the higher valuation. Analyst inference
2. Check whether Canaccord changes its Hold rating in a later update; that would signal a shift in its recommendation beyond the reported increase in Amgen’s price target. Analyst inference
3. Watch for further Canaccord ratings actions on Amgen, as the supplied report links to its analyst-ratings page but gives no forecast details or reason for the target increase. Analyst inference

Evidence

• Original source link unavailable